Ohad Hammer

Ohad Hammer
Contributor since: 2007
Onyx - A 'Must Own' Biotech For 2013
Winners Of ESMO 2012
Synta - The Signal Looks Real
Winners Of ASCO 2012
Drugs To Watch At ASCO 2012
Biotech Stocks To Watch In 2012
AVEO: More Open Questions Than Answers
Exelixis: Setting The Facts Straight
Why It's Time to Sell ImmunoGen
Drugs to Watch at ASCO 2011